Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 4/20 | 0.42 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.39 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
| ▸ | FABP7 | O15540 | 3/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.35 |
| ▸ | FABP3 | P05413 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23105031 | 0.81 | BACE1 (0.42) | BACE1HTR1DIKBKETBK1KCNH2 | |
| SCHEMBL14720958 | 0.81 | BACE1 (0.42) | BACE1HTR1DIKBKETBK1KCNH2 | |
| SCHEMBL970743 | 0.81 | HTR1D (0.40) | BACE1HTR1DIKBKETBK1KCNH2 | |
| SCHEMBL20092136 | 0.77 | AAK1 (0.40) | BACE1HTR1DIKBKETBK1KCNH2 | |
| SCHEMBL15507834 | 0.77 | ALDH1A1 (0.54) | BACE1HTR1DIKBKETBK1AAK1 | |
| SCHEMBL14320398 | 0.77 | BACE1 (0.42) | BACE1HTR1DIKBKETBK1KCNH2 | |
| SCHEMBL4772120 | 0.77 | HTR2C (0.46) | BACE1HTR1DIKBKETBK1KCNH2 | |
| SCHEMBL26560458 | 0.76 | HTR1D (0.43) | BACE1HTR1DIKBKETBK1KCNH2 | |
| SCHEMBL8651066 | 0.76 | KMT2A (0.56) | BACE1IKBKETBK1FABP7FABP5 | |
| SCHEMBL30047103 | 0.75 | PIK3CA (0.45) | BACE1IKBKETBK1KCNH2PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250361237-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | ORIGENIS GMBH (DE) | 2025-11-27 | — | — | US | disclosed |
| US-12384788-B2 | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease | ORIGENIS GMBH (DE) | 2025-08-12 | — | — | US | disclosed |
| EP-4327884-A2 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASES | Origenis GmbH (DE) | 2024-02-28 | — | — | EP | disclosed |
| EP-4327884-A2 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASES | Origenis GmbH (DE) | 2024-02-28 | — | — | EP | disclosed |
| EP-4028017-B1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASES | ORIGENIS GMBH (DE) | 2023-12-06 | — | — | EP | disclosed |
| US-20220380374-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | ORIGENIS GMBH (DE) | 2022-12-01 | — | — | US | disclosed |
| US-20220380373-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | ORIGENIS GMBH (DE) | 2022-12-01 | — | — | US | disclosed |
| EP-4028016-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | Origenis GmbH (DE) | 2022-07-20 | — | — | EP | disclosed |
| EP-4028017-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | Origenis GmbH (DE) | 2022-07-20 | — | — | EP | disclosed |
| WO-2021048620-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | ORIGENIS GMBH (DE) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021048618-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | ORIGENIS GMBH (DE) | 2021-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384788-B2 | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as LRRK2, NUAK1 and/or TYK2 kinase modulators for the treatment of e.g. autoimmune disease | NUAK1, TYK2, MARK1 | BACE1 244/4885HTR1D 390/4885IKBKE 406/4885 |
| US-20220380374-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | NUAK1, TYK2, MARK1 | BACE1 244/4885HTR1D 391/4885IKBKE 412/4885 |
| US-20220380373-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | NUAK1, TYK2, MARK1 | BACE1 244/4885HTR1D 390/4885IKBKE 406/4885 |
| US-20250361237-A1 | 1,4-DIHYDROBENZO[D]PYRAZOLO[3,4-F][1,3]DIAZEPINE DERIVATIVES AND RELATED COMPOUNDS AS LRRK2, NUAK1 AND/OR TYK2 KINASE MODULATORS FOR THE TREATMENT OF E.G. AUTOIMMUNE DISEASE | NUAK1, TYK2, MARK1 | BACE1 244/4885HTR1D 390/4885IKBKE 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.